Aktis Oncology (NASDAQ:AKTS) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm issued an overweight rating and a $30.00 target price on the technology company’s stock.

Several other research analysts have also recently issued reports on the stock. Leerink Partners started coverage on shares of Aktis Oncology in a report on Tuesday. They set an “outperform” rating and a $31.00 target price for the company. TD Cowen began coverage on Aktis Oncology in a research report on Tuesday. They set a “buy” rating on the stock. Wall Street Zen raised Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Finally, Bank of America started coverage on Aktis Oncology in a research note on Tuesday. They issued a “buy” rating and a $34.00 target price on the stock. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $31.67.

Aktis Oncology Price Performance

AKTS opened at $20.90 on Tuesday. Aktis Oncology has a 12-month low of $18.52 and a 12-month high of $29.16.

Insider Buying and Selling

In other Aktis Oncology news, major shareholder Ansbert Gadicke purchased 1,112,777 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the purchase, the insider directly owned 10,260,064 shares in the company, valued at approximately $184,681,152. This trade represents a 12.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ecor1 Capital, Llc purchased 2,222,222 shares of Aktis Oncology stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average cost of $18.00 per share, with a total value of $39,999,996.00. Following the acquisition, the director directly owned 4,348,658 shares in the company, valued at $78,275,844. This trade represents a 104.50% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 6,117,776 shares of company stock valued at $110,119,968 in the last ninety days.

Key Headlines Impacting Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Several major firms initiated coverage with bullish ratings and high price targets — Bank of America (Buy, $34 PT), Leerink Partners (Outperform, $31 PT), and JPMorgan (Overweight, $30 PT) — implying 43–63% upside vs. the current price, giving institutional validation to AKTS’s strategy and growth potential.
• Positive Sentiment: TD Cowen started coverage with a Buy, highlighting Aktis’s differentiated miniprotein radiopharma platform and projecting multi‑billion dollar sales potential; this initiation is also covered in TipRanks commentary. AKTS initiated with bullish view at TD Cowen — The Fly TipRanks coverage
• Positive Sentiment: Leerink and JPMorgan notes are summarized in market wire coverage, reinforcing the consensus bullish view from new analysts. Leerink/JPMorgan coverage — Benzinga
• Neutral Sentiment: Short-interest reports for early February show “0 shares” and NaN changes — likely data errors or reporting anomalies; current filings do not provide reliable evidence of elevated short pressure or a squeeze scenario.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.